Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 13/20 | 0.41 |
| ▸ | ITGAV | P06756 | 13/20 | 0.41 |
| ▸ | ITGB6 | P18564 | 13/20 | 0.41 |
| ▸ | ITGB1 | P05556 | 7/20 | 0.40 |
| ▸ | ITGA5 | P08648 | 7/20 | 0.40 |
| ▸ | ITGB5 | P18084 | 7/20 | 0.40 |
| ▸ | ITGB8 | P26012 | 7/20 | 0.40 |
| ▸ | ITGA8 | P53708 | 7/20 | 0.40 |
| ▸ | F7 | P08709 | 4/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | GPR139 | Q6DWJ6 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL6777786 | 0.89 | ITGB3 (0.49) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL3835297 | 0.88 | GPR139 (0.44) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL7345376 | 0.87 | ITGB3 (0.51) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6779336 | 0.81 | ITGB3 (0.49) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6777948 | 0.79 | ITGB3 (0.55) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL16918488 | 0.79 | ITGB3 (0.45) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL7344055 | 0.78 | F7 (0.46) | F7F2L3MBTL1GPR139 | |
| SCHEMBL6773288 | 0.77 | ITGB3 (0.52) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6780556 | 0.77 | ITGB3 (0.52) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL15456810 | 0.77 | ITGB3 (0.54) | ITGB3ITGAVITGB6ITGB1ITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6831199-B1 | In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 | G. D. SEARLE & CO. | 2004-12-14 | — | — | US | disclosed |
| EP-0850221-B1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | SEARLE & CO (US) | 2001-07-18 | — | — | EP | disclosed |
| US-6028223-A | AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS | G. D. SEARLE & CO. (US) | 2000-02-22 | — | — | US | disclosed |
| EP-0850221-A1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1998-07-01 | — | — | EP | disclosed |
| WO-1997008145-A1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1997-03-06 | — | — | WO | disclosed |